WAVEMAN · COMPANY

ATTO · Attovia Therapeutics, Inc.

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

ATTO

Name: Attovia Therapeutics, Inc. (ATTO) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Attovia Therapeutics, Inc.

PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0002058707

CLUSTER · 6 INSIDERSACTIVIST 13DFORM 144 · 1☆ WATCH

INSIDER NET · 180D

$64.0M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

XBRL, annual

NET MARGIN

CONVERSIONS · 180D

codes C/M, not in net · $0 priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$64.0M over 180 days

+$64.0M over 90 days · +$31.8M of it by a 10%+ holder

more than 98% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

fewer than five institutions report holding it

REVENUE

no revenue reported in any filing

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

no share repurchases reported

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

6 insiders bought a net $64.0M, but 1 Form 144 notice ($2.2M) are queued to sell.

Frazier Life Sciences Public Fund, L.P. disclosed a 5%+ stake (1.7%) in the last six months.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +10.5%

+10.5%12M

INSIDER BUYINSIDER SELL13D/G STAKEFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

6 insiders reported buying shares.

The record shows a net $64.0M bought by insiders over 180 days, $2.2M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Attovia Therapeutics, Inc. insiders bought a net $64.0M of stock across 101 Form 4 purchases and sales, with 6 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

Frazier Life Sciences XI, L.P.

—

BUY

2026-08-06

588,235.0

$10.0M

Sanofi

—

BUY

2026-08-06

300,000.0

$5.1M

Redmile Group, LLC

—

BUY

2026-08-06

200,000.0

$3.4M

Redmile Group, LLC

—

BUY

2026-08-06

400,000.0

$6.8M

venBio Global Strategic Fund IV, L.P.

—

BUY

2026-08-06

382,352.0

$6.5M

101 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 96 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

no 13F holders found for this ticker

5%+ owners

13D = intent to influence · 13G = passive

Frazier Life Sciences Public Fund, L.P.

ACTIVIST 13D · 2026-08-11

1.7%

FHMLSP, L.P.

ACTIVIST 13D · 2026-08-11

1.7%

FHMLSP, L.L.C.

ACTIVIST 13D · 2026-08-11

1.7%

Frazier Life Sciences XI, L.P.

ACTIVIST 13D · 2026-08-11

13.5%

FHMLS XI, L.P.

ACTIVIST 13D · 2026-08-11

13.5%

Planned sales · Form 144

Filed before the sale — intent, not a trade

GOLDMAN SACHS GROUP INC

FILED 2026-08-28

$2.2M

Clinical pipeline

ClinicalTrials.gov · 2 registered trials, 2 still enrolling or running — a status change here is dated weeks before the press release

Phase 1

2 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED